Status:
COMPLETED
Gabapentin for Bipolar & Cannabis Use Disorders
Lead Sponsor:
Medical University of South Carolina
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Bipolar I Disorder
Bipolar II Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The proposed 2-week, double-blind, crossover, proof of concept study aims to measure and manipulate core neurochemical (i.e., dysregulated brain GABA/glutamate homeostasis) and neurobehavioral (i.e., ...
Detailed Description
Bipolar disorder (BD) is the Axis I condition most strongly associated with cannabis use disorder (CUD); there is a six-fold increase in the prevalence of CUD in individuals with BD relative to the ge...
Eligibility Criteria
Inclusion
- Meets DSM-V criteria for Bipolar Disorder
- Meets DSM-V criteria for Cannabis Use Disorder
- Using at least one mood stabilizing medication
Exclusion
- Serious medical or non-inclusionary psychiatric disease
- Concomitant use of benzodiazepine medications or any medications hazardous if taken with gabapentin
- History of clinically significant brain injury
- Presence of non-MRI safe material, or clinically significant claustrophobia.
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2019
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT03334721
Start Date
October 1 2017
End Date
July 1 2019
Last Update
November 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425